Clinical Trial

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

Study acronym: CD19-CARNK/T
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT06464861
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
Enrollment 52 participants
Start Date 2024-06-20
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-07